phrykt

Mirum Pharmaceuticals, Inc. (MIRM): who owns it and who trades it

As of Nov 16, 2026, MIRM insiders reported 61 open-market sales worth $44.7M and 1 purchase worth $9M in the last 12 months, with 61% of the sale value made under pre-set 10b5-1 plans. The largest seller was Christopher Peetz (CEO), with $18.1M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Mirum Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MIRM

323 funds and institutions reported MIRM shares worth $8.4B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Frazier Life Sciences Management, L.P. with 12.6%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Frazier Life Sciences Management, L.P.12.6%
Jupiter Topco LLC9.7%
BlackRock, Inc.7.2%
FMR LLC (Fidelity)6.0%
T. Rowe Price Associates4.4%
Vanguard Portfolio Management LLC3.9%
Vanguard Capital Management LLC3.7%
State Street Corp3.6%
William Blair Investment Management, LLC2.3%
Geode Capital Management, LLC2.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Frazier Life Sciences Management, L.P.7.68M12.59%$899MNo change
Jupiter Topco LLC5.91M9.69%$692M–
BlackRock, Inc.4.39M7.20%$514M+14%
FMR LLC (Fidelity)3.67M6.02%$430M+87%
T. Rowe Price Associates2.66M4.35%$311M+55%
Vanguard Portfolio Management LLC2.38M3.90%$278M+66%
Vanguard Capital Management LLC2.25M3.70%$264M-7%
State Street Corp2.17M3.56%$254M+12%
William Blair Investment Management, LLC1.40M2.30%$164M+318%
Geode Capital Management, LLC1.39M2.29%$163M+11%
Invesco Ltd.1.36M2.24%$160M+378%
Wellington Management Group LLP1.31M2.15%$153M-2%
Eventide Asset Management, LLC1.25M2.05%$146M-11%
Tang Capital Management LLC1.24M2.03%$145MNo change
Capital World Investors1.15M1.89%$135M+59%
Franklin Resources Inc1.15M1.89%$135M+61%
Novo Holdings A/s1.12M1.84%$132M-15%
TCG Crossover Management, LLC1.06M1.74%$124MNo change
Bvf Inc1.06M1.73%$124M-33%
Polar Capital Holdings Plc845,5241.39%$99M+198%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MIRM insiders reported $9M of open-market purchases and $44.7M of sales. 61% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$9M
1 trades, 1 people
Sales, 12 months
$44.7M
61 trades, 8 people
Sales under a 10b5-1 plan
61%
Share of sale value
Latest trade
Nov 11, 2026
Filed Nov 13, 2026

Purchases and sales by month

$9M$9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 11, 2026Laura BregeDirectorSale10,907$94.05$1MForm 4
Nov 11, 2026Laura BregeDirectorSale3,260$94.74$309KForm 4
Nov 4, 2026Christopher PeetzCEOSale plan20,000$90.00$1.8MForm 4
Sep 14, 2026Eric BjerkholtCFOSale9,943$98.37$978KForm 4
Sep 2, 2026Jolanda HoweVice presidentSale plan658$100.00$65.8KForm 4
Sep 1, 2026Christopher PeetzCEOSale plan8,312$98.08$815KForm 4
Sep 1, 2026Christopher PeetzCEOSale plan21,688$98.91$2.1MForm 4
Aug 18, 2026Jolanda HoweVice presidentSale40,000$100.00$4MForm 4
Aug 11, 2026Eric BjerkholtCFOSale plan6,001$99.90$599KForm 4
Aug 10, 2026Christopher PeetzCEOSale plan6,017$99.25$597KForm 4
Aug 10, 2026Christopher PeetzCEOSale plan11,683$98.51$1.2MForm 4
Aug 10, 2026Christopher PeetzCEOSale plan2,300$100.14$230KForm 4
Aug 3, 2026Jolanda HoweVice presidentSale plan1,840$105.29$194KForm 4
Jul 6, 2026Christopher PeetzCEOSale plan12,134$121.65$1.5MForm 4
Jul 6, 2026Christopher PeetzCEOSale plan4,181$122.34$512KForm 4
Jul 6, 2026Christopher PeetzCEOSale plan1,710$124.79$213KForm 4
Jul 6, 2026Christopher PeetzCEOSale plan1,975$123.74$244KForm 4
Jul 6, 2026Eric BjerkholtCFOSale plan300$124.94$37.5KForm 4
Jul 6, 2026Eric BjerkholtCFOSale plan528$123.84$65.4KForm 4
Jul 6, 2026Eric BjerkholtCFOSale plan1,048$122.43$128KForm 4
Jul 6, 2026Eric BjerkholtCFOSale plan3,124$121.67$380KForm 4
Jul 1, 2026Jolanda HoweVice presidentSale plan2,721$120.00$327KForm 4
Jun 17, 2026Jolanda HoweVice presidentSale plan2,594$101.95$264KForm 4
Jun 8, 2026Eric BjerkholtCFOSale plan1,175$93.95$110KForm 4
Jun 8, 2026Eric BjerkholtCFOSale plan2,258$92.84$210KForm 4
Jun 8, 2026Eric BjerkholtCFOSale plan1,567$95.12$149KForm 4
Jun 1, 2026Christopher PeetzCEOSale plan883$99.66$88KForm 4
Jun 1, 2026Christopher PeetzCEOSale plan1,021$98.20$100KForm 4
Jun 1, 2026Christopher PeetzCEOSale plan1,973$97.56$192KForm 4
Jun 1, 2026Christopher PeetzCEOSale plan6,926$96.15$666KForm 4
Jun 1, 2026Christopher PeetzCEOSale plan16,595$95.34$1.6MForm 4
Jun 1, 2026Christopher PeetzCEOSale plan2,602$94.64$246KForm 4
Jun 1, 2026Saira RamasastryDirectorSale3,977$100.00$398KForm 4
May 15, 2026Saira RamasastryDirectorSale plan2,000$109.47$219KForm 4
Apr 15, 2026Saira RamasastryDirectorSale plan2,000$96.90$194KForm 4
Mar 16, 2026Saira RamasastryDirectorSale plan2,000$90.76$182KForm 4
Mar 16, 2026Eric BjerkholtCFOSale7,287$91.98$670KForm 4
Mar 16, 2026Peter RadovichPresidentSale16,515$91.98$1.5MForm 4
Mar 16, 2026Jolanda HoweVice presidentSale4,732$91.98$435KForm 4
Mar 16, 2026Christopher PeetzCEOSale40,985$91.98$3.8MForm 4
Feb 13, 2026Saira RamasastryDirectorSale plan2,000$102.09$204KForm 4
Feb 2, 2026Peter RadovichPresidentSale2,631$103.30$272KForm 4
Feb 2, 2026Christopher PeetzCEOSale9,108$103.30$941KForm 4
Feb 2, 2026Jolanda HoweVice presidentSale968$103.30$100KForm 4
Jan 26, 2026Eric BjerkholtCFOSale1,053$96.19$101KForm 4
Jan 26, 2026Peter RadovichPresidentSale3,143$96.19$302KForm 4
Jan 26, 2026Jolanda HoweVice presidentSale842$96.19$81KForm 4
Jan 26, 2026Christopher PeetzCEOSale6,831$96.19$657KForm 4
Jan 23, 2026Patrick J HeronDirectorPurchase131,425$68.48$9MForm 4
Jan 22, 2026Jolanda HoweVice presidentSale926$93.33$86.4KForm 4
Jan 22, 2026Joanne QuanCHIEF MEDICAL OFFICERSale1,822$93.33$170KForm 4
Jan 22, 2026Eric BjerkholtCFOSale1,421$93.33$133KForm 4
Jan 22, 2026Peter RadovichPresidentSale2,382$93.33$222KForm 4
Jan 22, 2026Christopher PeetzCEOSale7,098$93.33$662KForm 4
Jan 20, 2026Joanne QuanCHIEF MEDICAL OFFICERSale6,911$90.27$624KForm 4
Jan 15, 2026Saira RamasastryDirectorSale plan2,000$90.99$182KForm 4
Dec 22, 2025Saira RamasastryDirectorSale plan5,000$80.00$400KForm 4
Dec 19, 2025Michael G GreyDirectorSale plan50,000$78.00$3.9MForm 4
Dec 18, 2025Saira RamasastryDirectorSale plan1,000$69.46$69.5KForm 4
Dec 18, 2025Saira RamasastryDirectorSale plan1,000$70.00$70KForm 4
Dec 1, 2025Michael G GreyDirectorSale plan50,000$74.00$3.7MForm 4
Nov 21, 2025Michael G GreyDirectorSale plan50,000$70.00$3.5MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Christopher PeetzCHIEF EXECUTIVE OFFICER, Director–$18.1MNov 4, 2026
Michael G GreyDirector–$11.1MDec 19, 2025
Patrick J HeronDirector$9M–Jan 23, 2026
Jolanda HoweSVP, GLOBAL CONTROLLER–$5.6MSep 2, 2026
Eric BjerkholtCHIEF FINANCIAL OFFICER–$3.6MSep 14, 2026
Peter RadovichPRESIDENT AND COO–$2.3MMar 16, 2026
Saira RamasastryDirector–$1.9MJun 1, 2026
Laura BregeDirector–$1.3MNov 11, 2026
Joanne QuanCHIEF MEDICAL OFFICER–$794KJan 22, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MIRM short interest

Moderate short interest. 10.0% of MIRM shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 20%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.52M MIRM shares were sold short, 10.0% of the shares outstanding, down 2.1% from the report before. At the average daily volume of 551,116 shares, buying them all back would take about 11.8 trading days (days to cover).

Shares short, % of all shares

9.99%May 15Oct 3014.0%

Days to cover

11.8May 15Oct 3014.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.52M9.99%-2%551,11611.8
Oct 15, 20266.66M10.26%-5%912,8497.3
Sep 30, 20266.99M10.76%+11%910,9207.7
Sep 15, 20266.28M9.67%+2%523,88912.0
Aug 31, 20266.17M9.51%-5%467,19213.2
Aug 14, 20266.49M9.99%-5%892,8527.3
Jul 31, 20266.82M10.51%-6%566,26012.1
Jul 15, 20267.27M11.93%-3%686,48210.6
Jun 30, 20267.48M12.27%+8%1.49M5.0
Jun 15, 20266.91M11.33%+5%614,94311.2
May 29, 20266.56M10.76%-20%828,2727.9
May 15, 20268.20M13.44%-3%1.70M4.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Mirum Pharmaceuticals company events

Mirum Pharmaceuticals filed 19 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026AnnouncementAnnouncement that Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at American Association for the Study of Liver Diseases On November 10, 2026, Mirum Pharmaceuticals, Inc. announced that the primary endpoint was met in the Phase 3 AZURE-4 study… Filing
  2. Nov 3, 2026ResultsReleased financial results. Filing
  3. Oct 26, 2026AnnouncementAnnouncement of Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva On October 26, 2026, Mirum Pharmaceuticals, Inc. announced positive results from Cohort 2 of the pivotal… Filing
  4. Oct 13, 2026AnnouncementMirum Pharmaceuticals, Inc. announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia. Filing
  5. Sep 28, 2026AnnouncementMirum Pharmaceuticals, Inc. and Incyte Corporation announced that the U.S. Food and Drug Administration approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans… Filing
  6. Sep 8, 2026LeadershipMirum Pharmaceuticals, Inc. announced that, on September 2, 2026, the Company’s Board of Directors appointed Rob Myers, M.D., to succeed Joanne Quan, M.D., as the Company’s Chief Medical Officer, effective upon Dr. Myers’ beginning employment with the Company, which employment is expected to begin… Filing
  7. Aug 5, 2026ResultsReleased financial results. Filing
  8. Jun 18, 2026VoteReported shareholder vote results. Filing
  9. May 18, 2026AgreementMirum Pharmaceuticals, Inc. issued $690.0 million of its 0.00% Convertible Senior Notes due 2032, which includes the full exercise of the initial purchasers’ option to purchase up to an additional $90.0 million of Notes. Filing
  10. May 6, 2026ResultsReleased financial results. Filing
  11. May 4, 2026AnnouncementMirum Pharmaceuticals, Inc. announced the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational oral ileal bile acid transporter inhibitor, in patients with primary sclerosing cholangitis. Filing
  12. Apr 27, 2026AnnouncementMirum Pharmaceuticals, Inc. announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an investigational monoclonal antibody designed to bind hepatitis B surface antigen (HBsAg), for the treatment of chronic hepatitis delta virus (HDV). Filing
  13. Feb 25, 2026ResultsReleased financial results. Filing
  14. Jan 26, 2026DealMirum Pharmaceuticals, Inc. completed the previously announced acquisition of Bluejay Therapeutics, Inc., a Delaware corporation, contemplated by the Agreement and Plan of Merger and Reorganization, dated December 6, 2025, by and among the Company, Bjork Merger Sub I, Inc., a Delaware corporation… Filing
  15. Jan 12, 2026ResultsReleased financial results. Filing
  16. Dec 19, 2025AnnouncementIn November 2025, Mirum Pharmaceuticals, Inc. announced that it received a Paragraph IV Certification Notice Letter from Sandoz, Inc., providing notification to the Company that Sandoz has submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration, seeking approval of a… Filing
  17. Dec 19, 2025AgreementMirum Pharmaceuticals, Inc. entered into a subscription agreement with entities associated with TCG Crossover Management, LLC, an institutional investor, pursuant to which the PIPE Investors have agreed, subject to the terms and conditions of the Subscription Agreement, to purchase immediately… Filing
  18. Dec 8, 2025AgreementMirum Pharmaceuticals, Inc. entered into an Agreement and Plan of Merger and Reorganization with Bjork Merger Sub I, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company, Bjork Merger Sub II, LLC, a Delaware limited liability company and a direct wholly owned subsidiary… Filing
  19. Nov 17, 2025AnnouncementMirum Pharmaceuticals, Inc. received a Paragraph IV Certification Notice Letter from Sandoz, Inc. providing notification to the Company that Sandoz has submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to manufacture, use or sell a generic… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Mirum Pharmaceuticals financials

Famous investors that hold MIRM

5 of the 50 well-known investors we track reported holding MIRM in their latest 13F filing. The largest position is Steve Cohen's, worth $46.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026546,005$46.7M0.1%New
Jim Simons · Renaissance TechnologiesQ3 2026361,385$30.9M0.0%-18%
Ken Fisher · Fisher Asset ManagementQ3 2026196,199$16.8M0.0%+138%
Israel Englander · Millennium ManagementQ3 2026153,266$13.1M0.0%+59%
Ken Griffin · Citadel AdvisorsQ3 202698,219$8.4M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named MIRM in the last 120 days.

FiledHolderFormStake
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A8.5%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A8.5%

Questions about Mirum Pharmaceuticals, Inc. (MIRM) stock

Who owns the most MIRM stock?

The largest reported owner of Mirum Pharmaceuticals, Inc. (MIRM) is Frazier Life Sciences Management, L.P., with 12.6% of the company. In total, 323 funds and institutions reported holding MIRM at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are MIRM insiders buying or selling?

In the last 12 months, MIRM insiders reported 1 open-market purchase worth $9M and 61 sales worth $44.7M. The latest trade was on Nov 11, 2026. See every trade.

What is the short interest in MIRM?

As of Oct 30, 2026, 6.52M MIRM shares were sold short, 10.0% of the shares outstanding, down 2.1% from the report before. At the average daily volume of 551,116 shares, buying them all back would take about 11.8 trading days (days to cover). See the history.

Which famous investors hold MIRM?

5 of the 50 well-known investors we track reported MIRM in their latest 13F filing, including Steve Cohen, Jim Simons, Ken Fisher. The largest position is worth $46.7M. See all holders.

Executive pay

Mirum Pharmaceuticals's chief executive was paid a total of $10.4M for the year ended Dec 31, 2025, up 58% from $6.6M the year before. In the last 12 months, Mirum Pharmaceuticals's executives and directors bought $9M of stock on the open market and sold $44.7M.

Chief executive, total pay$10.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$29.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.